Thread by @WorldStrokeEd

#WeekendLecture
#ISC22
Highlights

300 invited talks
Nearly 200 oral abstracts
>1000 posters
Here we review some of trials and presentation from Main Events at #ISC22

#ISC22 Highlights
#RESCUE_Japan LIMIT
EVT for acute LVO with #large ischemic #Core

NIHSS>6, #ASPECT 3-5 , CT or MRI (~85%)
<6hr, or DWI/FLAIR mismatch <24hr
🚶mRS 0-3 at 90d: 31 vs 12.8%, RR 2.43🩸sICH,<48hr: 9 vs 4.9% NS
⚫️Death: 18 vs 23.5%, NS

nejm.org/doi/full/10.10…

#ISC22 Highlights
#Rescue-BT EVT with or w/o #tirofiban in LVO stroke
GPIIb/IIIa-R inhibitor could ⏬reocclusion after MT
55🏥in🇨🇳AIS<24hr, no IVT, ASPECT≥6
950pts
🚶mRS at 90d: 3 vs 3
🩸sICH: 9.7 vs 6.4%, NS
⚫️Death: 18.1 vs 16.9%
Treatment effect modification in LAA subgroup

#ISC22 Highlights
#PREMIERS
#Periodontal treatment to eliminate minority inequality & rural disparities in stroke
PD⬆️risk: stroke, MI, death
Standard vs intensive treatment of “gum disease"
280pt
NS diffs in outcomes
☝️# of dental visits correlates w/⏬ in composite outcome

#ISC22 Highlights
Economic evaluation of the #BEST_MSU study
Determine ⬆️ cost & effectiveness associated with MSU vs SM using CE analysis
✅Incremental Cost Effectiveness Ratio:📈Cost/📈QALYs
👉MSU cost effective specially in patient with no disability at baseline (mRS 0-1)

#ISC22 Highlights
#ACTION_CVT
Retrospective observational multicenter international study
#DOAC or warfarin for #CVT
845pts
Recurrent VTE or CVT: aHR 0.94,ns
Complete/partial renacalization: aHR 0.92,ns
Major hemorrhage: aHR 0.35; p 0.02
Death: 0.78,ns
👇
ahajournals.org/doi/abs/10.116…

#ISC22 Highlights
#CHOICE Trial
IA alteplase (0.225mg/kg)after successful MT
Aim: improve reperfusion in microvascular bed
Multicenter,RPCT, 2b
LVO w/ TICI2b or 2b/3 post MT
121pts (61% of sample size)
mRS 0-1 at 3m: 59 vs 40.4% p:0.47
sICH<24hr: 0 vs 3.8%
jamanetwork.com/journals/jama/…

#ISC22 Highlights

#CHABLIS_T , phase 2, 🇨🇳

#TNK 0.25 & 0.32mg/kg, no placebo, 4.5-24hr, (+)ve mismatch on CTP
Outc:
-EVT: ⏬50% hypoperfusion volume in control CTP
+EVT: TICI≥2b at initial angio
👉32.6% Low Dose; 23.3% High Dose
🩸sICH: 11.6% LD; 9,3 HD

#ISC22 Highlights
#Onyx For The EV Management Of #cAVM

140pts, not previously treated, 60% symptomatic
3 groups: Onyx embo only as curative (73), pre NSx, pre RSx
⚫️All SAE related to procedure: 7.1%
⚫️Death 4/140 (related to procedure:1)
✅Total cure 75%

#ISC22 Highlights
#BUBL study
Robotic assisted #TCD vs TTE to detect right➡️left shunt
raTCD (+) for RLS in 63.% vs 20.9% in #TTE
TTE missed 18/35 of large shunts detected by raTCD
No SAE associated to device
Technically feasible for use by health professionals with no TCD skills

#ISC22 Highlights
#EXCELLENT registry, EmboTrap
~1000pts
55% treated <6h
✅≥TICI2b 94%
#CLOT:
🩸RBC rich—> aumenta deformability/friability—>better outcome
🗜️Platelet rich-> more compressed—> modified effects of RBC clot % on outcome

#WeekendLecture
#ISC22 Highlights

A lot more of science and knowledge was shared during this #ISC22
If you missed you still can access via On Demand
professional.heart.org/en/meetings/in…

Thanks for reading!!